Taconic to Sell Medicyte's Hepatocyte Cell Strains | GenomeWeb

NEW YORK (GenomeWeb News) – Taconic and Medicyte announced a sales and marketing agreement covering Medicyte's products.

Under the terms of the deal, Taconic will promote and sell Medicyte's human primary Upcyte hepatocyte cell strains and corresponding media, which have been developed for in vitro applications. According to the companies, the deal strengthens Taconic's tADMET portfolio of models, and expands Medicyte's distribution and market visibility, while at the same time providing entry into new markets for its hepatocyte cell strains.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.